COVID-19 treatment

July 22, 2020

Study to explore how COVID affects cognition over time

The Critical Illness, Brain Dysfunction and Survivorship Center at Vanderbilt University Medical Center is following patients who have been hospitalized for COVID-19 over time to see if they develop long-term cognitive impairment, depression or post-traumatic stress disorder (PTSD).

By Nancy Humphrey
July 22, 2020

New data offer insights on COVID treatments for people with cancer

Newly released data on treatment outcomes of people with cancer diagnosed with COVID-19 reveal a racial disparity in access to Remdesivir, an antiviral drug that has been shown to shorten hospital stays, and increased mortality associated with dexamethasone, a steroid that has had the opposite effect in the general patient population.

By Tom Wilemon
July 16, 2020

Investigational glaucoma drug studied to prevent respiratory distress in COVID-19 patients

Vanderbilt University Medical Center is evaluating razuprotafib, a drug being investigated for the treatment of glaucoma, in a new randomized, investigational trial for the prevention and treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19.

By VUMC News and Communications
July 15, 2020

Antibody research at Vanderbilt University Medical Center shows promise in fight against COVID-19

Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.

By Bill Snyder
July 15, 2020

Vanderbilt University Medical Center to recruit up to 1,000 volunteers for COVID-19 vaccine Trial

In late July, Vanderbilt University Medical Center will begin recruiting up to 1,000 volunteers in a late-stage study of an experimental COVID-19 vaccine developed by Moderna Inc. in collaboration with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

By Bill Snyder
July 9, 2020

New study supports remdesivir as COVID-19 treatment

This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.

By Bill Snyder
July 9, 2020

Coordinated care network ensures COVID-positive patient makes recovery

On March 27, Nashville resident Bill Boyce, 73, earned the unwelcome distinction of becoming the first patient intubated on Vanderbilt University Medical Center’s dedicated COVID-19 unit.
By Jill Clendening
July 9, 2020

New space bolsters infectious disease and immunology discovery

The Vanderbilt Institute for Infection, Immunology and Inflammation (VI4) recently moved into its new research and administrative home.
By Leigh MacMillan
July 2, 2020

Fe y Salud webinar addresses disproportionate effects of COVID-19 on Latino community

The Latino community is affected disproportionately by COVID-19. News outlets report leaders and lawmakers calling its impact “catastrophic.” In the state of Tennessee, one-third of residents who test positive for the coronavirus are Hispanic, even though only 5.6 percent of the population is Hispanic.
By Matt Schorr
June 24, 2020

VICTR named to key role to streamline COVID-19 research response

The Vanderbilt Institute for Clinical and Translational Research (VICTR), which provides comprehensive support for clinical and translational research at Vanderbilt University Medical Center (VUMC), has been named Administrative Coordinating Center (ACC) of a national effort to streamline the research response to life-threatening lung and heart problems caused by COVID-19.
By Bill Snyder
June 21, 2020

Major U.S. trial closes showing no benefit for hydroxychloroquine in COVID-19

The Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID) trial stopped enrolling new patients based on the fourth scheduled interim analysis showing no evidence of benefit or harm. 
By VUMC News and Communications
June 17, 2020

Initial COVID-19 testing data show impact in Nashville’s minority communities

Early data assessing the primary language of those who received COVID-19 tests at Vanderbilt University Medical Center, and tested positive, illustrates the disproportionate impact the pandemic is having on racial or ethnic communities.
By Holly Fletcher
June 12, 2020

TERAVOLT registry tracks outcomes of treatments among people with thoracic cancers sickened by COVID-19

New data from TERAVOLT, a global consortium that tracks outcomes of people with thoracic cancers affected by COVID-19, offers clues as to why they experienced a high death rate of 33% when the coronavirus swept across Europe.
By Tom Wilemon
1 … 7 8 9 10 11 12